Proceedings - Boulder Peptide Foundation

BPS 2018

Design and clinical application of SOLNATIDE, a new peptide for treatment of critical pulmonary dysfunctions

Bernhard Fischer

CEO, APEPTICO

ABSTRACT

Dysfunction of the epithelial sodium channel (ENaC), which regulates salt and water homeostasis in epithelia, causes several human pathological conditions, including pulmonary oedema and impaired alveolar gas exchange. SOLNATIDE is a 17 residue peptide and has been designed in silico based on the lectin-like domain of TNF. Various derivatives of SOLNATIDE have been synthesized. SOLNATIDE peptides demonstrated to activate ENaC in several experimental cell-based and animal models of lung oedema, ischemia reperfusion injury (IRI), high altitude pulmonary oedema (HAPE) and pseudohypoaldosteronism (PHA), as well in clinical studies in patients with pulmonary oedema and Acute Respiratory Distress Syndrome (ARDS) and in patients with primary graft dysfunction (PGD) following lung transplantation.

BIO

Professor Dr. Bernhard Fischer is a biotechnology expert and entrepreneurial pharma manager with long standing record in international life science biotechnology and pharmaceutical companies. In the course of his career he headed senior management positions in biopharmaceutical research and development, regulatory affairs, chemistry manufacturing & controls documentation and technical drug development. During his professional development he was research biochemist at the Institute of Molecular Biology and Institute of Biotechnology in Germany, Higher Scientific Officer at the Department of Protein Engineering of the AFRC in the United Kingdom, Head of the Department of Recombinant Proteins at the Biomedical Research Center of Baxter in Austria, Manager Chemistry Manufacturing & Controls and Manager Regulatory Affairs at Sandoz (Novartis) in Austria, Chief Technical Officer at Avidis in France, Vice President Development and Chief Technical Officer at Fibrex Medical in Austria.
Since 2008, Dr. Fischer serves as founder and CEO of APEPTICO, a Vienna based biotechnology company with focus on identification, preclinical and clinical development of proprietary peptide-based medicines for the treatment of various life-threatening pulmonary conditions.
Dr. Fischer is author of numerous scientific publications in the field of biotechnology and drug development. He is inventor and co-inventor of patents and patent applications in biotechnology and life science.
Dr. Fischer is Lecturer for Protein Chemistry and Bio-Medicinal Drug Development and Regulatory Affairs at various Universities and Business Schools. Dr. Fischer has a Master degree in Business Administration from the Open University Business School (UK). He is member of the Middle European Society of Regulatory Affairs (MEGRA), the Societies of Biotechnology and Biochemistry, the Austrian Biotech Industry (ABI), the European Respiratory Society (ERS) and the American Thoracic Society (ATS).

Oral Presentations in Scientific Sessions

The session topics for Scientific Program are Peptides in the Clinic, Drug Delivery, Chemistry of Complex Peptides, Spotlight on Discovery, and Peptide Showcase. Abstracts may be submitted via the Apply to Present page on the website. Submissions will be reviewed by the Scientific Advisory Board on a monthly basis and the speaker will be notified of a decision.

Presentation length: Format is 25-30 minutes slide presentation with 5-10 minutes for Q&A, with the exception of Peptide Showcase talks which are 10 minute slide presentations with 5 minutes for Q&A. Please confirm with your session chair to confirm the exact presentation length.

Invited Speakers: Speakers are requested to supply their presentation details 30 days after receiving an invitation to present.

Program Book Deadline: Final abstract and title must be provided no later than September 1st. No changes to the program are possible after this date.

Presentation Format: Oral presenters please provide your presentation slides to the A/V table on the day of your presentation.

Lodging: All speakers are requested to reserve their own room. Discount rates at the conference hotel are available until August 16th.

Registration: All speakers, excluding sponsored presentation speakers, receive a complimentary registration upon approval of the abstract.

Peptide Showcase Description

The Peptide Showcase is an opportunity for an individual or company to “showcase” new ideas, technology and pipeline assets. Priority shall be given to presentations from biotech and startup companies. Service providers and vendors are not eligible. Speakers in the session receive a complimentary event registration.

Posters

Posters can be presented on any topic relevant to peptides including original research, innovative products and technologies.

Eligibility- Any attendee (from academia, industry, biotech or vendor/sponsor) can present a poster. The presentation must contain original scientific thinking. To submit a poster go to the Submit a Poster link from the meeting menu. All submissions are reviewed on a rolling basis and will be notified of approval. September 1st is the last day to submit a poster abstract. Approved posters are published on the BPF website.

A 30 ” x 40″ board shall be provided with thumb tacks. Board will be on an easel and can be rotated for either landscape or portrait formats. Once you apply for a poster, you will get email confirmation that your poster was accepted. The poster session and number assignments will be emailed one week before the Symposium.

Poster boards shall be available for display from 8am to 8pm the day of your assigned poster session. See the program agenda for the poster session schedule.

Public Release

Every presentation at the Boulder Peptide Symposium is automatically recorded. Speakers are required to give consent for sharing of the presentation video with the peptide community.